Health risks of anabolic steroid use by amateur athletes.

Published: 07-10-2015 Last updated: 14-04-2024

Niet van toepassing.

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Other condition
Study type	Observational invasive

Summary

ID

NL-OMON45186

Source ToetsingOnline

Brief title Anabolic steroids and health risks.

Condition

- Other condition
- Endocrine and glandular disorders NEC
- Anxiety disorders and symptoms

Synonym ergogenic substances., Use/abuse of: anabolic-androgenic steroids

Health condition

middelengebruik

Research involving

Human

Sponsors and support

Primary sponsor: Kennemer Gasthuis **Source(s) of monetary or material Support:** Posthumus Meyjes Fonds;Spaarne Gasthuis Academy;RIVM;Medial Diagnostische Centra

Intervention

Keyword: Anabolic steroids, Health, Testosteron

Outcome measures

Primary outcome

Niet van toepassing.

Secondary outcome

Niet van toepassing.

Study description

Background summary

Niet van toepassing.

Study objective

Niet van toepassing.

Study design

Niet van toepassing.

Study burden and risks

Niet van toepassing.

Contacts

Public

Kennemer Gasthuis

Boerhaavelaan 22 Haarlem 2035RC NL **Scientific** Kennemer Gasthuis

Boerhaavelaan 22 Haarlem 2035RC NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

- Male gender.

- Minimum age of 18 years at inclusion.

- The planned anabolic steroid cycle should meet the following requirements:

o At least 1 cycle with an expected duration of at least 6 weeks, containing at least 2 anabolic steroids, namely testosterone, methyltestosterone, metenolone, boldenone [Equipoise], nandrolone [Deca-durabolin], mesterolone, oxymetholone, oxandrolone [Anavar], dehydrochlorotestosterone [Turinabol], stanozolol [Winstrol], trenbolone [Finaplix] and/or methandienone [Dianabol].

o During the cycle at least 200 mg of testosterone (undecanoate) should be used weekly(supraphysiological dosage) or other drug with equivalent dosage.

Exclusion criteria

- Anabolic steroid use in 3 months prior to inclusion.

- Irresponsible anabolic steroid use.

Study design

Design

Study type: Observational invasive		
Masking:	Open (masking not used)	
Control:	Uncontrolled	
Primary purpose:	Treatment	

Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	21-10-2015
Enrollment:	100
Туре:	Actual

Ethics review

Approved WMO Date:	07-10-2015
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO Date:	25-04-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	10-11-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register CCMO **ID** NL49593.094.15